Article Versions Notes

Kirchhoff D, Stelte-Ludwig B, Lerchen H-G, Wengner AM, Ahsen Ov, Buchmann P, Märsch S, Mahlert C, Greven S, Dietz L, et al. IL3RA-Targeting Antibody–Drug Conjugate BAY-943 with a Kinesin Spindle Protein Inhibitor Payload Shows Efficacy in Preclinical Models of Hematologic Malignancies. Cancers. 2020; 12(11):3464. https://doi.org/10.3390/cancers12113464

Kirchhoff, Dennis, Beatrix Stelte-Ludwig, Hans-Georg Lerchen, Antje Margret Wengner, Oliver von Ahsen, Pascale Buchmann, Stephan Märsch, Christoph Mahlert, Simone Greven, Lisa Dietz, and et al. 2020. "IL3RA-Targeting Antibody–Drug Conjugate BAY-943 with a Kinesin Spindle Protein Inhibitor Payload Shows Efficacy in Preclinical Models of Hematologic Malignancies" Cancers 12, no. 11: 3464. https://doi.org/10.3390/cancers12113464

Kirchhoff, D., Stelte-Ludwig, B., Lerchen, H.-G., Wengner, A. M., Ahsen, O. v., Buchmann, P., Märsch, S., Mahlert, C., Greven, S., Dietz, L., Erkelenz, M., Zierz, R., Johanssen, S., Mumberg, D., & Sommer, A. (2020). IL3RA-Targeting Antibody–Drug Conjugate BAY-943 with a Kinesin Spindle Protein Inhibitor Payload Shows Efficacy in Preclinical Models of Hematologic Malignancies. Cancers, 12(11), 3464. https://doi.org/10.3390/cancers12113464